60 Degrees Pharmaceuticals (NASDAQ:SXTP) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Ascendiant Capital Markets lowered their price target on shares of 60 Degrees Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of 60 Degrees Pharmaceuticals in a research report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Thursday, November 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, 60 Degrees Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $4.50.

60 Degrees Pharmaceuticals Stock Performance

NASDAQ:SXTP opened at $1.05 on Tuesday. The company has a market cap of $4.44 million, a PE ratio of -0.14 and a beta of 2.79. The stock has a 50-day simple moving average of $1.39 and a 200 day simple moving average of $1.74. 60 Degrees Pharmaceuticals has a 52-week low of $0.85 and a 52-week high of $12.45.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.21) by $0.55. The firm had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.38 million. On average, research analysts predict that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.